Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Malcolm Anderson

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
The New Zealand Medical Journal|July 12, 2019
Investigating strategies to improve clinical trial opportunities for patients with cancer in New Zealand-INSIGHTYeojeong Jane So, Michael Jameson, Vincent Newton, et al.
Molecular & Cellular Proteomics : MCP|June 29, 2023
Structural Premise of Selective Deubiquitinase USP30 Inhibition by Small-Molecule BenzosulfonamidesDarragh P O'Brien, Hannah B L Jones, Franziska Guenther, et al.
Journal of Molecular Biology|December 21, 2010
Engineering a high-affinity anti-IL-15 antibody: crystal structure reveals an α-helix in VH CDR3 as key component of paratopeDavid C Lowe, Stefan Gerhardt, Alison Ward, et al.
JMIR Cancer|March 3, 2025
Treatment Outcomes From Erlotinib and Gefitinib in Advanced Epidermal Growth Factor Receptor-Mutated Nonsquamous Non-Small Cell Lung Cancer in Aotearoa New Zealand From 2010 to 2020: Nationwide Whole-of-Patient-Population Retrospective Cohort StudyPhyu Sin Aye, Joanne Barnes, George Laking, et al.
JMIR Research Protocols|July 2, 2024
Erlotinib or Gefitinib for Treating Advanced Epidermal Growth Factor Receptor Mutation-Positive Lung Cancer in Aotearoa New Zealand: Protocol for a National Whole-of-Patient-Population Retrospective Cohort Study and Results of a Validation SubstudyPhyu Sin Aye, Joanne Barnes, George Laking, et al.
Bioorganic & Medicinal Chemistry Letters|August 28, 2003
Imidazo[1,2-a]pyridines: a potent and selective class of cyclin-dependent kinase inhibitors identified through structure-based hybridisationMalcolm Anderson, John F Beattie, Gloria A Breault, et al.
Bioorganic & Medicinal Chemistry Letters|December 13, 2005
SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitorsNicola M Heron, Malcolm Anderson, David P Blowers, et al.
Journal of Medicinal Chemistry|February 20, 2015
Small molecule binding sites on the Ras:SOS complex can be exploited for inhibition of Ras activationJon J G Winter, Malcolm Anderson, Kevin Blades, et al.
Bioorganic & Medicinal Chemistry Letters|September 26, 2008
Imidazoles: SAR and development of a potent class of cyclin-dependent kinase inhibitorsMalcolm Anderson, David M Andrews, Andy J Barker, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
The New Zealand Medical Journal|July 12, 2019
Investigating strategies to improve clinical trial opportunities for patients with cancer in New Zealand-INSIGHTYeojeong Jane So, Michael Jameson, Vincent Newton, et al.
Molecular & Cellular Proteomics : MCP|June 29, 2023
Structural Premise of Selective Deubiquitinase USP30 Inhibition by Small-Molecule BenzosulfonamidesDarragh P O'Brien, Hannah B L Jones, Franziska Guenther, et al.
Journal of Molecular Biology|December 21, 2010
Engineering a high-affinity anti-IL-15 antibody: crystal structure reveals an α-helix in VH CDR3 as key component of paratopeDavid C Lowe, Stefan Gerhardt, Alison Ward, et al.
JMIR Cancer|March 3, 2025
Treatment Outcomes From Erlotinib and Gefitinib in Advanced Epidermal Growth Factor Receptor-Mutated Nonsquamous Non-Small Cell Lung Cancer in Aotearoa New Zealand From 2010 to 2020: Nationwide Whole-of-Patient-Population Retrospective Cohort StudyPhyu Sin Aye, Joanne Barnes, George Laking, et al.
JMIR Research Protocols|July 2, 2024
Erlotinib or Gefitinib for Treating Advanced Epidermal Growth Factor Receptor Mutation-Positive Lung Cancer in Aotearoa New Zealand: Protocol for a National Whole-of-Patient-Population Retrospective Cohort Study and Results of a Validation SubstudyPhyu Sin Aye, Joanne Barnes, George Laking, et al.
Bioorganic & Medicinal Chemistry Letters|August 28, 2003
Imidazo[1,2-a]pyridines: a potent and selective class of cyclin-dependent kinase inhibitors identified through structure-based hybridisationMalcolm Anderson, John F Beattie, Gloria A Breault, et al.
Bioorganic & Medicinal Chemistry Letters|December 13, 2005
SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitorsNicola M Heron, Malcolm Anderson, David P Blowers, et al.
Journal of Medicinal Chemistry|February 20, 2015
Small molecule binding sites on the Ras:SOS complex can be exploited for inhibition of Ras activationJon J G Winter, Malcolm Anderson, Kevin Blades, et al.
Bioorganic & Medicinal Chemistry Letters|September 26, 2008
Imidazoles: SAR and development of a potent class of cyclin-dependent kinase inhibitorsMalcolm Anderson, David M Andrews, Andy J Barker, et al.
Pageof 3